Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer
نویسندگان
چکیده
منابع مشابه
Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis.
We aim to evaluate the efficacy and safety of paclitaxel-based doublet intravenous chemotherapy (IVC) with and without intraperitoneal chemotherapy (IPC) as the first-line treatment in advanced gastric cancer (AGC) with peritoneal metastasis (PM). 173 AGC patients with peritoneal metastasis were enrolled. All patients received paclitaxel-based doublet systemic chemotherapy Among them, 117 patie...
متن کاملPaclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients
AIMS AND BACKGROUND This study was designed to compare the efficacy and safety of paclitaxel/oxaliplatin/fluorouracil (TOF) regimen and S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer (GC) patients. METHODS Sixty patients were divided into TOF group and SOX groups randomly. Patients in the TOF group received paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, ...
متن کاملOutcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
PURPOSE Little is known about outcomes in the use of third-line chemotherapy in cases of advanced gastric cancer (AGC). The primary aim of this retrospective study was to evaluate outcomes of docetaxel-based chemotherapy in patients with AGC that progressed after both oxaliplatin-based and irinotecan-based regimens. MATERIALS AND METHODS Eligible patients were those with AGC who had previous ...
متن کاملCapecitabine and oxaliplatin for advanced gastric and oesophageal (oesophago-gastric) cancer - 6th draft.pub
• Gastric and oesophageal cancer are the fifth and ninth most common cancers in the UK – audit data from English Cancer Registries show that in 2005 there were 4680 patients diagnosed with gastric cancer and 6375 diagnosed with oesophageal cancer. Most patients present with advanced, inoperable or metastatic disease – in 2005 only 20% of patients that presented with this disease underwent surgi...
متن کاملComparing adverse effects of docetaxel-doxorubicin and paclitaxel-doxorubicin regimens in breast cancer patients
Introduction: Taxanes have emerged as one of the most active agents in the treatment of patients with breast cancer. Nevertheless, questions remain with regard to their toxicity profiles. This study aimed to compare prevalence and severity of adverse effects of two chemotherapy regimens including taxanes (docetaxel or paclitaxel) in breast cancer patients. Materials and Methods: Fifty patients ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Gastroenterology
سال: 2011
ISSN: 1007-9327
DOI: 10.3748/wjg.v17.i8.1082